查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1588404

無菌注射契約製造的市場規模、佔有率和趨勢分析報告：按分子類型、給藥途徑、治療用途、最終用途、地區和細分市場進行預測，2025-2030

Sterile Injectable Contract Manufacturing Market Size, Share & Trends Analysis Report Molecule Type (Small Molecule, Large Molecule), By Route Of Administration, By Therapeutic Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

無菌注射劑契約製造市場的成長和趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球無菌注射契約製造市場規模將達319億美元，2025年至2030年複合年成長率為12.28%。

無菌注射合約製造業的推動因素包括注射劑管道和核准的增加、生技藥品和生物學名藥需求的增加、開發新療法的研發活動投資的契約製造以及細胞和基因治療需求的增加是推動因素。無菌注射劑的契約製造市場較為分散，多家公司擁有類似的技術力和加工能力。

具有管理高效價藥物等獨特能力的契約製造組織（CMO）預計將主導該行業。歐洲和美國有各種無菌注射劑 CMO，並擁有歐盟 GMP 和美國FDA 批准的設施。此外，印度和中國等新興經濟體預計在預測期內將出現良好的成長。這是由於這些國家對注射藥品採購服務的需求不斷增加。印度有超過20家獲得歐盟GMP/美國FDA注射認證的CMO。由於製藥巨頭對新興市場具有成本效益的外包服務的需求不斷成長，印度的無菌注射契約製造製造業正在迅速擴張。儘管印度大多數注射劑 CMO 一直在迎合當地需求，但近年來這種轉變變得明顯。

COVID-19 大流行對無菌注射劑契約製造製造業產生了積極影響。這是由於 2020 年至 2021 年對 COVID-19 疫苗的需求大幅增加。市場主要參與者也正在採取合併、收購和聯盟等無機策略舉措來增強其市場地位。此外，近年來，多家公司專注於進入注射劑契約製造製造業。例如，全球私人投資公司 Bridgewest Group 宣布推出專門從事無菌注射劑的新合約開發和受託製造廠商(CDMO) 設施。

無菌注射契約製造市場報告亮點

  • 按分子類型分類，大分子細分市場以 2024 年最大的銷售佔有率 67.07% 引領市場。該行業的成長主要歸因於契約製造製造商在聚合物治療藥物開發方面的投資增加、注射生技藥品管道的擴大以及美國FDA 對生物相似藥的核准大幅增加。
  • 從治療應用來看，腫瘤領域以2024年最大的銷售佔有率28.17%引領市場。癌症患者數量的增加、研發投資的增加以及對癌症藥物和生技藥品的需求不斷成長是推動該行業成長的因素之一。
  • 從給藥途徑來看，靜脈注射(IV) 細分市場在 2024 年以 30.35% 的最大銷售佔有率引領市場。多個醫療保健系統正在轉向個人化醫療，推動了對客製化靜脈治療的需求。
  • 以最終用途分類，製藥公司細分市場以 2024 年最高收益佔有率43.48% 領先市場。為了專注於研發等核心能力，製藥公司擴大將藥物開發和製造業務委託給契約製造組織（CMO）。
  • 北美無菌注射契約製造市場將在 2024 年佔據主導地位，銷售佔有率將達到 42.86%。該地區的成長得益於先進的醫療基礎設施、研發投資的增加、技術的發展以及大公司的存在等因素。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 無菌注射契約製造市場的變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 無菌注射契約製造市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第 4 章：無菌注射契約製造市場：分子類型估計與趨勢分析

  • 細分儀表板
  • 全球無菌注射劑契約製造市場分子型波動分析
  • 2018-2030年全球無菌注射契約製造市場規模及趨勢分析（依分子類型）
  • 低分子
  • 大分子

第5章 無菌注射劑契約製造市場：治療應用的估計和趨勢分析

  • 細分儀表板
  • 全球無菌注射契約製造市場治療應用波動分析
  • 2018-2030年全球無菌注射合約契約製造市場規模與趨勢分析（依治療應用）
  • 癌症
  • 糖尿病
  • 心血管疾病
  • 中樞神經系統疾病
  • 感染疾病
  • 肌肉骨骼
  • 抗病毒藥
  • 其他

第6章 無菌注射契約製造市場：給藥途徑預估及趨勢分析

  • 細分儀表板
  • 全球無菌注射劑契約製造市場給藥途徑變化分析
  • 2018-2030年全球無菌注射合約契約製造市場規模與趨勢分析（依管理途徑）
  • 皮下注射（SC）
  • 靜脈注射 (IV)
  • 肌肉注射 (IM)
  • 其他

第7章無菌注射契約製造市場：最終用途估計和趨勢分析

  • 細分儀表板
  • 全球無菌注射劑契約製造市場的最終用途變化分析
  • 2018-2030 年全球無菌注射契約製造市場規模和趨勢分析（按最終用途）
  • 製藥公司
  • 生物製藥公司
  • 其他

第 8 章無菌注射契約製造市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 公司/競爭對手分類
  • 策略規劃
  • 2024 年企業市場分析
  • 公司簡介
    • Baxter
    • Catalent, Inc.
    • Vetter Pharma
    • Recipharm AB
    • Aenova Group
    • Fresenius Kabi AG
    • Unither Pharmaceuticals
    • FAMAR Health Care Services
    • Cipla Inc.
    • NextPharma Technologies
Product Code: GVR-4-68040-097-0

Sterile Injectable Contract Manufacturing Market Growth & Trends:

The global sterile injectable contract manufacturing market size is expected to reach USD 31.9 billion by 2030, registering a CAGR of 12.28% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing pipeline and approvals of injectables, growing demand for biologics and biosimilars, rise in investment in research & development activities for the development of novel therapeutics, and increasing demand for cell & gene therapies are the key factors driving the growth of sterile injectable contract manufacturing industry. The market for sterile injectable contract manufacturing is fragmented, with several players having similar technological and processing capabilities.

Contract Manufacturing Organizations (CMOs) with unique capabilities, such as the management of high-potency drugs, are anticipated to dominate the industry. In Europe and the U.S., there are various sterile injectable CMOs with EU GMP and U.S. FDA-approved facilities. Moreover, developing economies such as India and China are anticipated to witness lucrative growth across the forecast period. This is attributable to the increasing demand for injectable sourcing services across these countries. India has over 20 CMOs with EU GMP/U.S. FDA injectable certifications. The Indian sterile injectable contract manufacturing industry is rapidly expanding due to rising demand for outsourcing services from the pharmaceutical giants to emerging markets for cost-effectiveness. Most Indian injectable CMOs have been catering to local demand, but the transition has been evident over the past few years.

The COVID-19 pandemic positively impacted the sterile injectable contract manufacturing industry. This was because of the huge surge in demand for COVID-19 vaccines from 2020 to 2021, as these vaccines are a major part of the injectables industry. In addition, major players in the market are adopting inorganic strategic initiatives such as mergers, acquisitions, and partnerships to enhance their market positions. Furthermore, for the past few years, several companies have focused on penetrating the injectable contract manufacturing industry. For instance, Bridgewest Group, a global private investment firm, announced the launch of a new contract development and manufacturing organization (CDMO) facility focused on sterile injectable drug products.

Sterile Injectable Contract Manufacturing Market Report Highlights:

  • Based on molecule type, the large molecule segment led the market with the largest revenue share of 67.07% in 2024. The growth of the segment is mainly due to rising investments by contract manufacturers in developing large molecule-based therapeutics, an expanding pipeline of biologics injectables, and a notable increase in U.S. FDA approvals for biosimilars.
  • Based on therapeutic application, the cancer segment led the market with the largest revenue share of 28.17% in 2024. The increasing number of cancer cases, rising R&D investments, and growing requirements for oncology drugs & biologics are some of the factors driving the segment growth.
  • Based on route of administration, the intravenous (IV) segment led the market with the largest revenue share of 30.35% in 2024. Several healthcare systems are shifting toward personalized medicine, which is boosting the demand for tailored intravenous therapies.
  • Based on end use, the pharmaceutical companies segment led the market with the largest revenue share of 43.48% in 2024. Pharmaceutical companies are increasingly outsourcing their drug development and manufacturing operations to Contract Manufacturing Organizations (CMOs) to focus on their core competencies, such as R&D.
  • North America sterile injectable contract manufacturing market dominated with the revenue share of 42.86% in 2024. The growth in the region is attributed to the factors such as to the region's advanced healthcare infrastructure, increasing R&D investment, technological developments, and the presence of major players.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Molecule Type Segment
    • 1.2.2. Molecule Therapeutic Application Segment
    • 1.2.3. Route of Administration Segment
    • 1.2.4. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Sterile Injectable Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Pipeline and Approvals of Injectables
      • 3.2.1.2. Growing Demand for Biologics and Biosimilars Significantly Supported Market Growth
      • 3.2.1.3. Rise in Investment Across Research & Development Activities for the Development of Novel Therapeutics
      • 3.2.1.4. Increasing Demand for Cell & Gene Therapies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Low Barriers to Market Penetration Have Resulted in Pricing Pressure
      • 3.2.2.2. Challenges Related to Quality Control
  • 3.3. Sterile Injectable Contract Manufacturing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Sterile Injectable Contract Manufacturing Market: Molecule Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Sterile Injectable Contract Manufacturing Market Molecule Type Movement Analysis
  • 4.3. Global Sterile Injectable Contract Manufacturing Market Size & Trend Analysis, by Molecule Type, 2018 to 2030 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Small molecule market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large molecule market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Sterile Injectable Contract Manufacturing Market: Therapeutic Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Sterile Injectable Contract Manufacturing Market Therapeutic Application Movement Analysis
  • 5.3. Global Sterile Injectable Contract Manufacturing Market Size & Trend Analysis, by Therapeutic Application, 2018 to 2030 (USD Million)
  • 5.4. Cancer
    • 5.4.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Diabetes
    • 5.5.1. Diabetes market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Cardiovascular Diseases
    • 5.6.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Central Nervous Systems Diseases
    • 5.7.1. Central nervous systems diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.8. Infectious Disorders
    • 5.8.1. Infectious disorders market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.9. Musculoskeletal
    • 5.9.1. Musculoskeletal market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.10. Anti-Viral
    • 5.10.1. Anti-Viral market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.11. Others
    • 5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Sterile Injectable Contract Manufacturing Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Sterile Injectable Contract Manufacturing Market Route of Administration Movement Analysis
  • 6.3. Global Sterile Injectable Contract Manufacturing Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Subcutaneous (SC)
    • 6.4.1. Subcutaneous (SC) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Intravenous (IV)
    • 6.5.1. Intravenous (IV) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Intramuscular (IM)
    • 6.6.1. Intramuscular (IM) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Sterile Injectable Contract Manufacturing Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Sterile Injectable Contract Manufacturing Market End Use Movement Analysis
  • 7.3. Global Sterile Injectable Contract Manufacturing Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Pharmaceutical Companies
    • 7.4.1. Pharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Biopharmaceutical Companies
    • 7.5.1. Biopharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Sterile Injectable Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. Regulatory Landscape
      • 8.4.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Regulatory Landscape
      • 8.4.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Competitive scenario
      • 8.4.4.3. Regulatory Landscape
      • 8.4.4.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory Landscape
      • 8.5.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Regulatory Landscape
      • 8.5.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. Regulatory Landscape
      • 8.5.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Regulatory Landscape
      • 8.5.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Regulatory Landscape
      • 8.5.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Regulatory Landscape
      • 8.5.7.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.8. Norway
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Competitive scenario
      • 8.5.8.3. Regulatory Landscape
      • 8.5.8.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key country dynamics
      • 8.5.9.2. Competitive scenario
      • 8.5.9.3. Regulatory Landscape
      • 8.5.9.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory Landscape
      • 8.6.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Regulatory Landscape
      • 8.6.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Competitive scenario
      • 8.6.4.3. Regulatory Landscape
      • 8.6.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Competitive scenario
      • 8.6.5.3. Regulatory Landscape
      • 8.6.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Competitive scenario
      • 8.6.6.3. Regulatory Landscape
      • 8.6.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Competitive scenario
      • 8.6.7.3. Regulatory Landscape
      • 8.6.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory Landscape
      • 8.7.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Regulatory Landscape
      • 8.7.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Competitive scenario
      • 8.8.2.3. Regulatory Landscape
      • 8.8.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Competitive scenario
      • 8.8.3.3. Regulatory Landscape
      • 8.8.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Competitive scenario
      • 8.8.4.3. Regulatory Landscape
      • 8.8.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key country dynamics
      • 8.8.5.2. Competitive scenario
      • 8.8.5.3. Regulatory Landscape
      • 8.8.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. Company Profiles/Listing
    • 9.4.1. Baxter
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Catalent, Inc.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Vetter Pharma
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Recipharm AB
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Aenova Group
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Fresenius Kabi AG
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Unither Pharmaceuticals
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. FAMAR Health Care Services
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Cipla Inc.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. NextPharma Technologies
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 4. Global Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 5. Global Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 6. Global Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 7. Global Sterile Injectable Contract Manufacturing, by region, 2018 - 2030 (USD Million)
  • Table 8. North America Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 9. North America Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 10. North America Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 11. North America Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 12. U.S. Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 13. U.S. Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 14. U.S. Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15. Canada Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 16. Canada Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 17. Canada Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 18. Canada Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 19. Mexico Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 20. Mexico Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 21. Mexico Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22. Mexico Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 23. Europe Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 24. Europe Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 25. Europe Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 26. Europe Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 27. Germany Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 28. Germany Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 29. Germany Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 30. Germany Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 31. UK Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 32. UK Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 33. UK Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34. UK Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 35. France Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 36. France Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 37. France Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 38. France Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 39. Italy Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 40. Italy Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 41. Italy Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 42. Italy Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 43. Spain Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 44. Spain Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 45. Spain Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46. Spain Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 47. Denmark Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 48. Denmark Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 49. Denmark Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50. Denmark Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 51. Norway Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 52. Norway Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 53. Norway Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 54. Norway Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 55. Sweden Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 56. Sweden Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 57. Sweden Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58. Sweden Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 59. Asia Pacific Sterile Injectable Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 60. Asia Pacific Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 61. Asia Pacific Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 64. China Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 65. China Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 66. China Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 67. China Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 68. Japan Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 69. Japan Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 70. Japan Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 71. Japan Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 72. India Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 73. India Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 74. India Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 75. India Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 76. South Korea Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 77. South Korea Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 78. South Korea Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 79. South Korea Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 80. Australia Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 81. Australia Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 82. Australia Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 83. Australia Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 84. Thailand Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 85. Thailand Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 86. Thailand Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 87. Thailand Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 88. Latin America Sterile Injectable Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 89. Latin America Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 90. Latin America Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 91. Latin America Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 92. Latin America Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 93. Brazil Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 94. Brazil Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 95. Brazil Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 96. Brazil Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 97. Argentina Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 98. Argentina Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 99. Argentina Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 100. Argentina Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 101. Middle East & Africa Sterile Injectable Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 102. Middle East & Africa Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 103. Middle East & Africa Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 104. Middle East & Africa Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 106. South Africa Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 107. South Africa Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 108. South Africa Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 109. South Africa Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 110. Saudi Arabia Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 111. Saudi Arabia Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 112. Saudi Arabia Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 114. UAE Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 115. UAE Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 116. UAE Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 117. UAE Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Sterile Injectable Contract Manufacturing Market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot 1
  • Fig. 14 Segment snapshot 2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Sterile Injectable Contract Manufacturing Market: Molecule Type outlook key takeaways
  • Fig. 20 Sterile Injectable Contract Manufacturing Market: Molecule Type movement analysis
  • Fig. 21 Small Molecule estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Large Molecule market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Sterile Injectable Contract Manufacturing Market: Therapeutic Application outlook key takeaways
  • Fig. 24 Sterile Injectable Contract Manufacturing Market: Therapeutic Application movement analysis
  • Fig. 25 Cancer estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Diabetes estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Cardiovascular Diseases estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Central Nervous Systems Diseases estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Infectious Disorders estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Musculoskeletal estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Anti-Viral estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Others estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sterile Injectable Contract Manufacturing Market: Route of Administration outlook key takeaways
  • Fig. 34 Sterile Injectable Contract Manufacturing Market: Route of Administration movement analysis
  • Fig. 35 Subcutaneous (SC) estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Intravenous (IV) estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Intramuscular (IM) estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Others estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sterile Injectable Contract Manufacturing Market: End Use outlook key takeaways
  • Fig. 40 Sterile Injectable Contract Manufacturing Market: End Use movement analysis
  • Fig. 41 Pharmaceutical Companies estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Biopharmaceutical Companies estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Others estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Regional marketplace outlook, 2024 & 2030 (USD Million)
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 North America Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 US Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Canada Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Mexico Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Europe Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 UK Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Germany Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 France Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Spain Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Italy Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Denmark Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Norway Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Sweden Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Asia Pacific Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Japan Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 China Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 India Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Australia Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Korea Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Thailand Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Latin America Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Brazil Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Argentina Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 MEA Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 South Africa Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Saudi Arabia Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 UAE Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 Kuwait Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Market participant categorization
  • Fig. 99 Sterile Injectable Contract Manufacturing Market Position Analysis, 2024
  • Fig. 100 Strategic framework